AMR Action Fund
More than 20 leading pharmaceutical companies launched a ground-breaking collective venture - the AMR Action Fund - to bridge the current gap in funding for the development of new antibiotics
Read More
COVID-19
IFPMA members commit to accelerate their effort to use their skills, technology and resources to bring safe, effective diagnostics, treatments and vaccines to patients around the world. Visit IFPMA COVID-19 Hub.
Read More
Global Biopharma CEO/Top Executives COVID-19 Media Briefing (28 May 2020)
On 28 May 2020, IFPMA organised a media briefing on the status of collaboration and risk-sharing to speed up the research, development and manufacturing of vaccines against COVID-19.
Watch more
PHARMA CEO/TOP EXECUTIVES GLOBAL RESPONSE TO COVID-19 - VIRTUAL PRESS BRIEFING
On 30 April 2020, the global biopharmaceutical industry, represented by high-level executives/ CEO’s, took part in a virtual media briefing on the status of COVID-19 treatments
Watch more
Pharma CEO/Top Executives Global Response to COVID-19 – Virtual Press Briefing
On 19 March 2020, the global biopharmaceutical industry, represented by high-level executives/ CEO’s, took part in a virtual media briefing highlighting industry’s efforts and future commitments to address the current global coronavirus (COVID-19) crisis.
Watch more
Collaborating to End Neglected Tropical Diseases
Progress has been significant in the fight against NTDs since the signing of the London Declaration in 2012. Our industry has been engaged in innovative collaborative partnerships, showcased in our new joint publication.
Read more
Meet #GenerationGavi
Over the past 20 years, IFPMA and its members have proudly worked with Gavi, The Vaccine Alliance, to protect the most valuable resource on earth thanks to life saving vaccines: its children.
Read More
IFPMA Code of Practice eLearning
Our Code of Practice has evolved over time and it promotes a culture grounded on values, principles and decisions based on good judgement. You can take our new eLearning here!
Start training hereIFPMA in Brief
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Tackling Global health challenges
The research-based biopharmaceutical industry is proud to be playing its part in the quest to find effective and sustainable solutions to today’s most pressing health concerns.
Read More
Boosting Innovation and Access
The research-based biopharmaceutical industry is thinking creatively about its innovation and business models to meet new challenges, and is working in collaboration with different players from the scientific community.
Read More
Strengthening Regulatory Systems
Patients everywhere should be treated with high quality medicines and vaccines. Science-based guidelines provide direction for the development, manufacture, and supply of medicines.
Read More
Ethics and Business Integrity
The healthcare community and the public must be confident that research-based biopharmaceutical industry and their employees, wherever they operate, communicate and act in an ethical and professional manner.
Read More
Discovering medicines and Vaccines
Never have people lived longer and never have so many children been saved from dying in the first years of life. Medicines and vaccines extend and improve the quality of life for many people.
Read More
Our Resources
IFPMA Code of Practice 2019
Read More
Health for All in Africa - Our collaborations supporting the SDGs
Read More
Message from Thomas Cueni at AMR Action Fund launch event in Tokyo on 10 July 2020 (Video)
Read More
Global Biopharmaceutical Industry pulling out all the stops to address Coronavirus public health crisis
19 March 2020, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, today confirmed that having already mobilized on an unprecedented scale to respond to the COVID-19 pandemic, they commit to do more. The biopharmaceutical industry commits to accelerate its effort to...
Read More
Greg Perry - IFPMA Moderated Panels @Pre-ICDRA 2018
Read More
IFPMA Statement on the launch of a new global collaboration to accelerate the development, production and equitable access to new COVID-19 tools
Geneva, 24 April 2020 Statement delivered by: Thomas Cueni, Director General, IFPMA The biopharmaceutical industry is acutely aware of the enormous responsibility we have to patients and society to engage in unprecedented levels of collaboration to find a solution to COVID-19. We stand ready to bring to this partnership our...
Read More
Join IFPMA
Our membership has three levels tailored to meet specific needs. Full Members have to be R&D-based pharmaceutical companies or national associations whose membership includes innovative pharmaceutical companies; Associate Members of R&D-based pharmaceutical companies and national associations whose permanent staff numbers are less than five, and Affiliate Members that are organizations, associations, companies and institutions who are supportive of the R&D-based
LEARN MOREOur Blog
Covid-19 vaccine: when, and for whom?
On 24 July, Thomas Cueni, IFPMA Director General, joined Imogen Foulkes for the Inside Geneva podcast on Swiss Info, to talk about the development, production and eventual distribution of COVID-19 vaccines. Their discussion highlighted the importance of broad-based collaborative efforts among all stakeholders as well as the vital necessity of leaving no one behind and prioritizing the most vulnerable worldwide. However, in this race against...
Read More
Chatham House: Weekly COVID-19 Pandemic Briefing – Perspective from the Pharmaceutical Industry
Published on Thomas Cueni’s LinkedIn profile. Last Wednesday, I sat down with @Chatham House’s @Emma Ross (moderator) and epidemiologist Professor @David L. Heymann to discuss the latest science and developments in the #COVID19 pandemic. During the interview, we discussed how the pharmaceutical industry is collaborating on an unprecedented scale to develop COVID-19 technologies and tools, the challenges and concerns the industry faces and the best approaches...
Read More
Reinforcing Business Integrity for APEC Health Systems Amidst COVID-19
Authors: Dr. Jeff Blackmer, Mr. Thomas Cueni, Mr. Gaston Fernandez, Ms. Nancy Travis, Mr. Russell Williams The dual health and economic crisis resulting from COVID-19 has brought into sharp focus the importance of ethical business conduct. Emergency government measures, widespread economic and social disruption, as well as unscrupulous actors taking advantage of the current situation for personal gain are testing business integrity for SMEs and...
Read MoreLatest Tweets
